Table 1 Responses and progression-free... | American Society of Hematology

Table 1

Responses and progression-free survival (PFS) in relapsed/ refractory CLL

Response	BR,² N = 78	FCR,⁶ N = 276	Ibrutinib,³ N = 85	FCR with ibrutinib,¹ N = 3	BR-ibrutinib,¹ N = 30
ORR, %	59	69.9	71	100	96.7*
CR, %	9	24.3	2.4	100†	40†
Median PFS, mo	15.2	30.6	Not reached (at month 26, 75% were progression free)	Not reached	Not reached (at month 12, 85.9% were progression free)

Response	BR,² N = 78	FCR,⁶ N = 276	Ibrutinib,³ N = 85	FCR with ibrutinib,¹ N = 3	BR-ibrutinib,¹ N = 30
ORR, %	59	69.9	71	100	96.7*
CR, %	9	24.3	2.4	100†	40†
Median PFS, mo	15.2	30.6	Not reached (at month 26, 75% were progression free)	Not reached	Not reached (at month 12, 85.9% were progression free)

Includes 1 patient with partial response and lymphocytosis.

Includes extended treatment period with ibrutinib.